These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28592067)

  • 1. [Combination of PP242 and dasatinib suppresses the progression of acute myeloid leukemia in a mouse model].
    Qu YH; Liu HT; He FC
    Zhonghua Yi Xue Za Zhi; 2017 May; 97(20):1584-1588. PubMed ID: 28592067
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of ADAR1 on the development of MLL-AF9 induced murine AML].
    Peng L; Yang X; Zhang Y; Hu T; Wang W; Wang X; Xu J; Cheng T; Yuan W; Gao Y
    Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):383-8. PubMed ID: 26031523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
    J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
    Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
    Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment of AML Mouse Model by Transplantation of Hematopoietic Cells from MLL-AF9 Transgenic Mice].
    Long WY; Shen X; Xing S; Xiong GL; Wang HG; Yu ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1369-1374. PubMed ID: 34627412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function.
    Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H
    Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
    Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
    Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells.
    Deng M; Xiao H; Peng H; Yuan H; Xiao X; Liu S
    Mol Cell Biochem; 2023 Apr; 478(4):851-860. PubMed ID: 36107284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of the retrovirus-mediated murine model with MLL-AF9 leukemia].
    Xu SM; Yang Y; Zhou M; Zhao XJ; Qin Y; Zhang PL; Yuan RF; Zhou JF; Fang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1126-32. PubMed ID: 24156419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
    Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
    Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
    Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia.
    Somintara S; Leardkamolkarn V; Suttiarporn P; Mahatheeranont S
    PLoS One; 2016; 11(1):e0146869. PubMed ID: 26752299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
    Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
    PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.